Callan Family Office LLC Buys New Stake in Natera, Inc. $NTRA

Key Points

• Callan Family Office LLC has acquired a new stake in Natera, Inc., purchasing 3,609 shares valued at approximately $610,000 in the second quarter.
• Natera reported a quarterly earnings loss of ($0.74) EPS, missing the consensus estimate and demonstrating a year-over-year revenue increase of 32.2%.
• Most analysts maintain a positive outlook for Natera, with a consensus price target of $192.88, indicating optimism about the company's performance.

Callan Family Office LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,609 shares of the medical research company's stock, valued at approximately $610,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. HighPoint Advisor Group LLC boosted its position in Natera by 30.8% in the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after buying an additional 468 shares during the period. Park Avenue Securities LLC purchased a new position in Natera in the 2nd quarter valued at approximately $1,525,000. Amalgamated Bank boosted its position in Natera by 9.8% in the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock valued at $1,173,000 after buying an additional 740 shares during the period. Comerica Bank boosted its position in Natera by 24.1% in the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock valued at $19,954,000 after buying an additional 27,379 shares during the period. Finally, GAMMA Investing LLC boosted its position in Natera by 32.3% in the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after buying an additional 207 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Price Performance

NASDAQ NTRA opened at $174.17 on Tuesday. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $183.00. The company has a market capitalization of $23.90 billion, a PE ratio of -91.19 and a beta of 1.74. The company has a fifty day moving average of $165.33 and a two-hundred day moving average of $157.54.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the prior year, the company earned ($0.30) EPS. The business's revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on NTRA shares. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target for the company in a research report on Monday, July 28th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Stephens reaffirmed an "overweight" rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Natera in a research report on Wednesday, October 8th. Finally, Barclays reaffirmed an "overweight" rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $192.88.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 14,083 shares of Natera stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total value of $2,253,280.00. Following the transaction, the chief executive officer directly owned 154,072 shares in the company, valued at approximately $24,651,520. The trade was a 8.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 3,045 shares of Natera stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the transaction, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. This represents a 4.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,464 shares of company stock worth $10,963,125. Insiders own 5.63% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.